Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Arcturus Therapeutics Holdings Inc. (ARCT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
15.70+0.60 (+3.97%)
At close: 04:00PM EDT
15.70 0.00 (0.00%)
After hours: 04:31PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close15.10
Open14.92
Bid14.83 x 1200
Ask16.66 x 800
Day's Range14.71 - 15.94
52 Week Range11.70 - 31.41
Volume209,882
Avg. Volume336,750
Market Cap416.921M
Beta (5Y Monthly)2.55
PE Ratio (TTM)N/A
EPS (TTM)-5.29
Earnings DateMar 28, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est39.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ARCT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Arcturus Therapeutics Holdings
    Daily – Vickers Top Buyers & Sellers for 11/29/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • Zacks

    Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?

    Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

  • Business Wire

    Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023

    SAN DIEGO, March 07, 2023--Arcturus Therapeutics Holdings Inc. (the "Company," "Arcturus," Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2022 after the market close on Tuesday, March 28 and will also host a conference call and webcast

  • Business Wire

    Arcturus Therapeutics to Attend Upcoming Investor Conferences

    SAN DIEGO, February 06, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences:

Advertisement
Advertisement